Power priors based on multiple historical studies for binary outcomes

Incorporating historical information into the design and analysis of a new clinical trial has been the subject of much recent discussion. For example, in the context of clinical trials of antibiotics for drug resistant infections, where patients with specific infections can be difficult to recruit, there is often only limited and heterogeneous information available from the historical trials. To make the best use of the combined information at hand, we consider an approach based on the multiple power prior that allows the prior weight of each historical study to be chosen adaptively by empirical Bayes. This choice of weight has advantages in that it varies commensurably with differences in the historical and current data and can choose weights near 1 if the data from the corresponding historical study are similar enough to the data from the current study. Fully Bayesian approaches are also considered. The methods are applied to data from antibiotics trials. An analysis of the operating characteristics in a binomial setting shows that the proposed empirical Bayes adaptive method works well, compared to several alternative approaches, including the meta-analytic prior.

[1]  Leonhard Held,et al.  Adaptive power priors with empirical Bayes for clinical trials , 2017, Pharmaceutical statistics.

[2]  Yuyan Duan,et al.  A Modified Bayesian Power Prior Approach with Applications in Water Quality Evaluation , 2005 .

[3]  Heinz Schmidli,et al.  On the Use of Co-Data in Clinical Trials , 2016 .

[4]  Joseph G Ibrahim,et al.  The power prior: theory and applications , 2015, Statistics in medicine.

[5]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[6]  James O. Berger,et al.  Rejection odds and rejection ratios: A proposal for statistical practice in testing hypotheses , 2015, Journal of mathematical psychology.

[7]  A. Dawid The Well-Calibrated Bayesian , 1982 .

[8]  James O. Berger,et al.  The interplay of Bayesian and frequentist analysis , 2004 .

[9]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[10]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[11]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[12]  Joseph G. Ibrahim,et al.  The relationship between the power prior and hierarchical models , 2006 .

[13]  R. Cuffe The inclusion of historical control data may reduce the power of a confirmatory study , 2011, Statistics in medicine.

[14]  J. Ramirez,et al.  Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia , 2013, Antimicrobial Agents and Chemotherapy.

[15]  D. Rubin Bayesianly Justifiable and Relevant Frequency Calculations for the Applied Statistician , 1984 .

[16]  M. Kieser,et al.  Blinded sample size recalculation in clinical trials incorporating historical data. , 2017, Contemporary clinical trials.

[17]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[18]  Yvette van Norden,et al.  Including historical data in the analysis of clinical trials: Is it worth the effort? , 2017, Statistical methods in medical research.

[19]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.

[20]  Andrew P Grieve,et al.  Idle thoughts of a ‘well‐calibrated’ Bayesian in clinical drug development , 2016, Pharmaceutical statistics.

[21]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[22]  Keying Ye,et al.  Evaluating water quality using power priors to incorporate historical information , 2006 .

[23]  Rosalind Walley,et al.  Addressing potential prior‐data conflict when using informative priors in proof‐of‐concept studies , 2017, Pharmaceutical statistics.

[24]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[25]  D. Spiegelhalter,et al.  Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .

[26]  M. V. van Driel,et al.  Antibiotics for ventilator-associated pneumonia. , 2016, The Cochrane database of systematic reviews.

[27]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[28]  H. Joe Dependence Modeling with Copulas , 2014 .